Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | SMO | Q99835 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005089 | 0.82 | CHRM2 (0.50) | CHRM4CHRM2CHRM1 | |
| SCHEMBL2249536 | 0.79 | MMP2 (0.44) | CTSBCTSSCTSKCHRM4 | |
| SCHEMBL3872566 | 0.79 | MMP2 (0.44) | CTSBCTSSCTSKCHRM4 | |
| SCHEMBL18436327 | 0.72 | CTSB (0.51) | CTSBCTSSCTSKCHRM4SCD5 | |
| SCHEMBL2247701 | 0.72 | GAA (0.41) | CTSBCTSSCTSKCHRM4SCD5 | |
| SCHEMBL3868817 | 0.71 | CHRM4 (0.37) | CTSBCTSSCTSKCHRM4SCD5 | |
| SCHEMBL2244313 | 0.71 | MMP2 (0.44) | CTSBCTSSCTSK | |
| SCHEMBL3869470 | 0.70 | MMP2 (0.43) | CHRM4MAPTFAAH | |
| SCHEMBL2242198 | 0.70 | MMP2 (0.43) | CHRM4MAPTFAAH | |
| SCHEMBL1005948 | 0.69 | SCD5 (0.39) | CTSBCTSSCTSKCHRM4SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844032-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-07-13 | — | — | EP | claimed |
| US-7868009-B2 | N-hydroxyamide derivatives and use thereof | Merck Serono, S.A. (CH) | 2011-01-11 | — | — | US | claimed |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | LABORATOIRES SERONO S.A. (CH) | 2008-04-17 | — | — | US | claimed |
| EP-1844032-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2007-10-17 | — | — | EP | claimed |
| WO-2006079653-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-08-03 | — | — | WO | claimed |
| US-8198280-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-06-12 | — | — | US | disclosed |
| US-8198280-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-06-12 | — | — | US | disclosed |
| US-8198280-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-06-12 | — | — | US | disclosed |
| EP-1844032-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-07-13 | — | — | EP | disclosed |
| US-20110086864-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086864-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086864-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-04-14 | — | — | US | disclosed |
| US-7868009-B2 | N-hydroxyamide derivatives and use thereof | Merck Serono, S.A. (CH) | 2011-01-11 | — | — | US | disclosed |
| US-7868009-B2 | N-hydroxyamide derivatives and use thereof | Merck Serono, S.A. (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | LABORATOIRES SERONO S.A. (CH) | 2008-04-17 | — | — | US | disclosed |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | LABORATOIRES SERONO S.A. (CH) | 2008-04-17 | — | — | US | disclosed |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | LABORATOIRES SERONO S.A. (CH) | 2008-04-17 | — | — | US | disclosed |
| EP-1844032-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079653-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006079653-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086864-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | CTSB 558/4885CTSS 1165/4885CTSK 1886/4885 |
| US-20080090838-A1 | N-Hydroxyamide Derivatives and Use Thereof | HNMT, ALOX5, HCAR2 | CTSB 829/4885CTSS 1327/4885CTSK 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.